EUVIMEDEUVIMED entdecken
Multizentrische Studie

Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes

J Cao, G Shao, H Zhong, L Davies Forsman, S Wang, S Dong, X Li, Z Ning, H Cao, Y Hu

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.24.0481 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von J Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

To evaluate currently recommended dosage using the population pharmacokinetics (PK) of bedaquiline (BDQ), clofazimine, cycloserine, linezolid (LZD) and moxifloxacin (MFX) in patients with multidrug-resistant TB (MDR-TB) and type II diabetes mellitus (DM).





METHODS

A prospective multi-centre PK study was conducted in China between 2016 and 2019. Population PK models were developed using nonlinear mixed-effect analyses based on the blood samples collected by rich sampling. The probability of target attainment (PTA) analysis was estimated using the Monte Carlo simulation.





RESULTS

A total of 1,450 plasma samples were collected from 58 participants with DM. Simulations showed that the WHO-recommended regimens of LZD (600 mg daily) and MFX (400 mg daily) achieved > 90% PTA for M. tuberculosis isolates with MICs below 0.50 and 0.25 mg/L, respectively. The currently recommended BDQ regimen (400 mg daily for 2 weeks, followed by 200 mg thrice weekly) might fail to achieve >90% PTA at an MIC of 0.06 mg/L or higher.





CONCLUSION

The population PK models for the five second-line drugs were established in Chinese patients with MDR-TB and DM. The model-based dosage evaluation showed that dosing adjustments may be necessary for isolates with borderline resistance levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, Multidrug-ResistantDiabetes Mellitus, Type 2HumansMaleFemaleMiddle AgedProspective StudiesAdultChinaMicrobial Sensitivity TestsAgedLinezolidMoxifloxacinMycobacterium tuberculosisMonte Carlo MethodYoung AdultClofazimineDose-Response Relationship, DrugDiarylquinolinesCycloserine

Substanzen

Antitubercular AgentsLinezolidMoxifloxacinbedaquilineClofazimineDiarylquinolinesCycloserine

Autor:innen und Institutionen

  • Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Guhua Hospital, Shanghai, China.
  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden;, Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden.
  • Zigong City Centre for Disease Control and Prevention, Zigong, Sichuan Province, China.

Zitieren

APA

Cao, J., Shao, G., Zhong, H., Davies Forsman, L., Wang, S., Dong, S., Li, X., Ning, Z., Cao, H., & Hu, Y. (2025). Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0481

Vancouver

Cao J, Shao G, Zhong H, Davies Forsman L, Wang S, Dong S, et al. Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.24.0481

BibTeX
@article{Cao2025,
  author = {Cao, J and Shao, G and Zhong, H and Davies Forsman, L and Wang, S and Dong, S and Li, X and Ning, Z and Cao, H and Hu, Y},
  title = {Population pharmacokinetics and dose evaluation for second-line TB drugs in patients with diabetes},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.24.0481}
}
Kostenlos starten →